Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + PD-1 antibody + GEMOX for unresectable intrahepatic cholangiocarcinoma
ChiCTR2100049873Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Aug 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib, gemcitabine and oxaliplatin in intrahepatic cholangiocarcinoma (ICC), sponsored by Tianjin Medical University General Hospital. Primary endpoint: objective response rate. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
lenvatinibgemcitabineoxaliplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2100049873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049873.